AzTrials
AzTrials

CHD - Congenital Heart DiseasePRISMNCT07686341

PRecision Integrated Saturation Monitor

An observational study of CHD - Congenital Heart Disease and Single Ventricle Heart Disease, run by Le Bonheur Children's Hospital at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to find out if an abdominal pulse oximeter device is as accurate as a conventional fingertip pulse oximeter in pediatric patients. In this study, we will be collecting data from your medical record while you are being treated in the hospital for your clinical care. Read more about this study

Who is it for?
Ages 0 to 12 months
What is being tested?
vital sign monitoring
Type of treatment
Medical device
How many people
100 participants
Where
1 siteUnited States
Study dates
Aug 2026to Dec 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 to 12 months
  • All sexes
  • No healthy volunteers
  • Child

Study population: Eligible infants hospitalized in the intensive care unit (PICU, PCVICU,NICU) who have already had an arterial line placed and on continuous pulse oximetry monitoring will be considered for enrollment and will be identified and approached for participation during their admission.

Who may be able to join

  • 0-12 months of age. (Must be less than 1 year of life for the pulse oximeter portion of the study) Weight greater than 2 Kg at time of study
  • Admitted to an intensive care unit. (Not applicable for outpatient cohort)
  • Arterial line in place as standard of care (Not applicable for outpatient cohort)
  • Informed consent provided by parent or LAR.

Who cannot join

  • Open Sternum
  • Skin abnormalities at the proposed sensor site (e.g., rash, eczema, wounds, stoma, or infection)
  • Known allergy or sensitivity to adhesives or materials used in the sensor
  • Excessive movement or irritability that precludes safe and effective placement of the sensor
  • Parent or legal guardian unable to provide informed consent

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site, 1 recruiting
  • Le Bonheur Children's Hospital

    Memphis, Tennessee, 38105

    Kara RN, 901-287-4594, Kara.lessel@mlh.org

    Recruiting

Other trials in United States

About this study

Official title: PRISM: PRecision Integrated Saturation Monitor A Novel Approach to Monitoring Oxygen Saturation in Children A Prospective, Observational, Comparative Validation Clinical Study to Evaluate the Accuracy of a Novel Abdominal Pulse Oximeter With Integrated Motion Detection and Skin Tone Calibration Against Arterial Blood Gas (SaO₂) Measurements and Conventional Fingertip Pulse Oximetry (SpO₂) in Pediatric Patients.

The purpose of this study is to find out if an abdominal pulse oximeter device is as accurate as a conventional fingertip pulse oximeter in pediatric patients. In this study, we will be collecting data from your medical record while you are being treated in the hospital for your clinical care. Your baby will be in the study for 3 days. There will be no additional study visits. We will collect information already being obtained while your baby is at the hospital.

Read the detailed description

Conventional pulse oximeters are prone to motion artifacts due to their placement on high-activity limbs. Traditionally, inpatient pulse oximetry relies on clinical staff to verify the accuracy of readings and distinguish between real and false desaturation events. However, in outpatient environments, caregivers are left to manage and interpret signals that may not provide reliable information about their child's health. PRISM aims to improve pulse oximetry monitoring for children. We will test an innovative pulse oximeter prototype that mitigates motion artifacts by shifting the monitoring location from a high-activity limb to the abdomen while incorporating motion detection capabilities. Previously, we have successfully developed an abdomen-worn prototype for collection of ECG signals for infant monitoring (Figure 1). We obtained high-quality signals with a robust correlation to the gold-standard ECG. Our preliminary results demonstrate the feasibility of collecting physiological signals from the abdomen, supporting its use as a novel, baby-friendly monitoring site. Figure 1. Comparison of ECG signals between gold-standard chest ECG and abdomen ECG. Protocol Version 2: 11 June 2026 IRB NUMBER: STUDY00000178 IRB APPROVAL DATE: 6/29/2026 IRB EXPIRATION DATE: 6/2/2027 We will incorporate a commercially available pulse oximetry sensor into a biocompatible, flexible, 3D printed housing. The child-focused design will be specific for application to the abdomen and will clip onto the diaper or pants of the baby; the tension from the diaper or pants will provide ample force to ensure sufficient contact between the device and the skin to achieve robust signals (Figure 2). The device will be removed with each diaper change. Figure 2. Schematic demonstrating the proposed pulse oximeter and its abdominal application As pulse oximetry uses optical sensors, external factors such as ambient light may interfere with data acquisition. Additionally, maintaining reliable contact with the skin is crucial to ensure the emitted light penetrates the underlying tissue, rather than reflecting off the skin's surface. Here, we will design the sensor housing to shield the pulse oximetry sensors from ambient light and provide a contact surface flexible enough for direct skin-to-sensor contact. The PRISM prototype is intended to minimize the impact of motion artifacts, a common phenomenon that leads to inaccurate readings and unnecessary alarms. By shifting the monitoring location from high-activity limbs to the more stable abdomen, we aim to enhance the accuracy and reliability of the device's measurements compared to traditional pulse oximeters. This design choice is particularly relevant for infants and young children, who often experience restlessness and movement during routine monitoring.

Successful accomplishment of this will result in a working prototype with motion artifact-resistant SpO2 reading error of less than 3.0% RMSE from SaO2. This development will allow the caregiver to continuously monitor accurate oxygen status Hypoxemic conditions, or medical problems stemming from low oxygen saturation, can result in half a million deaths annually. Oxygen saturation levels, which determine hypoxic conditions, can be measured directly from arterial blood. This is the gold standard of oxygen saturation measurement and is often called SaO2. Oxygen saturation measured from pulse oximetry, referred to as SpO2, uses light transmission and can allow for early detection of hypoxic conditions. It's a popular belief that melanin can absorb light in pulse oximetry, leading to the overestimation of SpO2 in darker skin. Although individuals with darker skin are observed to have a SpO2 overestimation, clinicians have yet to devise a method to accurately predict oxygen saturation given this overestimation[1]. Various clinical data has been curated to specifically address the issue of biases and disparities of pulse oximeter measurements in darker skin tones including the MIT Critical Datathon 2023 utilizing MIMIC IV and the blood-gas and oximetry linked dataset (BOLD)[2]. One issue with these datasets is race is often used as a proxy for skin tone, but there is great variability in skin color, even within a single race. Without an algorithm to account for how variation in skin tone biases in SpO2 measurement, a disproportionate amount of people of color may continue to receive incorrect diagnoses, leading to health inequities.

These incorrect diagnoses can lead to hidden hypoxemia, which is a condition where the gold standard oxygen saturation of a patient is less than 88% while the pulse oximeter measurement reads over 88%5. Studies show a significant disparity with black patients experiencing nearly three times the frequency of undetected hypoxemia compared to white patients6. They also emphasize the need to integrate pulse oximetry data with other clinical and patient-reported information to address this bias in medical technology.

These results are expected to generate evidence for proof-of-concept for this advanced next-generation pulse oximetry to be further tested and commercialized.

Being tested
vital sign monitoring
Keywords
monitoring device, pediatric chd, single ventricle, svhd
Medical subject headings
Heart Defects, Congenital, Univentricular Heart

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • vital sign monitoringDevice

    The intervention will be to evaluate abdominal SpO2 against both traditional fingertip readings and gold standard SaO2 measurements by collecting routine data from the medical chart that was performed as standard of care.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Abdominal SpO2 versus SaO2

    The primary outcome is the accuracy of abdominal SpO₂ versus SaO₂, measured as root mean square error (RMSE); target ≤ 3.0% RMSE.

    Measured: From enrollment to end of study at 72 hours.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jul 2026
  2. Study startAug 2026 (estimated)
  3. Primary completionAug 2028 (estimated)
  4. Study completionDec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07686341
Sponsor's protocol ID
STUDY00000178
Acronym
PRISM
Status last verified
Jun 2026
First submitted
30 Jun 2026
Last updated
7 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of CHD - Congenital Heart Disease and Single Ventricle Heart Disease, run by Le Bonheur Children's Hospital at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Abdominal SpO2 versus SaO2 (time frame: From enrollment to end of study at 72 hours.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in